Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.

百奧賽圖(北京)醫藥科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2315)

INSIDE INFORMATION
DETERMINATION OF THE OFFER SIZE AND OFFER PRICE FOR THE A SHARE OFFERING

This announcement is made by Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (the "**Company**") pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

References are made to the announcements dated March 6, 2023, March 15, 2023, June 20, 2023, September 17, 2025, November 3, 2025 and November 20, 2025 and the circulars dated March 31, 2023 and November 3, 2025 of the Company containing, among other things, related matters of the proposed Issue of A Shares and listing on the Sci-Tech Innovation Board of the Shanghai Stock Exchange. Unless otherwise defined, capitalized terms used in this announcement shall have the meanings as defined in the above announcements and circulars.

The Board is pleased to announce that, following the completion of the preliminary price consultations among inquiry targets on November 25, 2025, the Company will issue 47,500,000 new A Shares at the issue price of RMB26.68 per A Share. The issue price was negotiated and determined by the Company and the underwriter based on the results of the preliminary consultations, taking into account the fundamentals of the issuer, market conditions, valuations of listed companies in the same industry, needs for the proceeds, underwriting risks and other factors.

For the relevant terms of the A Share Offering, please refer to the full text of the A Share Prospectus of Biocytogen Pharmaceuticals (Beijing) Co., Ltd. for the Initial Public Offering and Listing of Stocks on the STAR Market (《百奧賽圖(北京)醫藥科技股份有限公司首次公開發行股票並在科創板上市招股意向書》) published by the Company in Chinese only on the website of the SSE (www.sse.com.cn), the HKEX news website of the Stock Exchange (www.hkexnews.hk) and the website of the Company (www.biocytogen.com) on November 20, 2025.

This announcement is for information purposes only and does not constitute any invitation or offer to acquire, purchase or subscribe for the securities of the Company. The Company will make further announcement(s) for any material update and development in relation to the A Share Offering in accordance with the Listing Rules and other applicable laws and regulations.

By order of the Board
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Shen Yuelei
Chairman of the Board, Chief Executive Officer and Executive Director

Hong Kong, 27 November, 2025

As at the date of this announcement, the Board comprises Dr. Shen Yuelei as chairman, chief executive officer and executive Director, Dr. Ni Jian and Dr. Zhang Haichao as executive Directors; Mr. Wei Yiliang, Dr. Zhou Kexiang and Ms. Zhang Leidi as non-executive Directors; Mr. Hua Fengmao, Dr. Yu Changyuan and Ms. Liang Xiaoyan as independent non-executive Directors.